Certara’s Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19

Rhea-AI Summary

Certara has confirmed through the Pitch study at Oxford University that its Vaccine Simulator predicted an optimal eight-week interval between COVID-19 vaccine doses. This finding challenges the existing dosing schedules of Pfizer-BioNTech and Moderna, which recommend three and four weeks, respectively. Certara's biosimulation technology integrates various data to optimize dosing strategies, aiding in global health efforts amidst the pandemic. The company aims to enhance vaccine efficacy and safety, including future booster recommendations and mixing vaccines.

Positive

• Certification of Vaccine Simulator predictions increases credibility.
• Technology supports global health initiatives, potentially increasing demand.
• Integration of large clinical data sets enhances predictive accuracy.

Negative

• None.

Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology

PRINCETON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that its Vaccine Simulator accurately predicted that eight weeks was the optimal timing between the first and second dose of COVID-19 vaccines. The Pitch study conducted at Oxford University in the United Kingdom confirmed Certara’s Vaccine Simulator prediction, which was released six months ago. Current dosing for the Pfizer-BioNTech and Moderna vaccines are spaced three and four weeks apart, respectively.

“The Pitch study results further validate that Certara’s biosimulation technology is a powerful, predictive tool to understand how vaccines and COVID-19 therapies work, enabling us to get dosing regimens right the first time,” said William F. Feehery, CEO of Certara. “We continue to invest in innovation to fight this ongoing pandemic and benefit global health.”

The Certara Vaccine Simulator, based upon the Company’s quantitative systems pharmacology (QSP) technology, integrates diverse inputs, including bioinformatics and in-vitro assays, to develop sophisticated models that answer ‘what-if’ scenarios to determine the best dosing strategies for various patient cohorts, such as the elderly and children. The Simulator has been used by a number of global pharmaceutical companies and its findings have been presented to regulatory agencies, including a U.S. Food and Drug Administration (FDA) workshop in June of 2021.

“Our Vaccine Simulator allows us to address critical questions on efficacy and safety of dosing regimens for different types of patients for COVID-19 as well as in other therapeutic areas. We have recently calibrated and validated our Vaccine Simulator with very large clinical data sets and added additional vaccine types,” said Piet van der Graaf, PharmD, PhD, senior vice president of QSP at Certara. “We also already have models to determine the optimal timing of COVID-19 vaccine boosters, what is the best way to mix and match vaccines, and what is required to maintain efficacy against COVID-19 variants.”

About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:

David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:

Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com

FAQ

What did the Pitch study at Oxford University confirm about Certara's Vaccine Simulator?

The Pitch study confirmed that Certara's Vaccine Simulator accurately predicted an eight-week optimal interval between COVID-19 vaccine doses.

How does Certara's Vaccine Simulator improve vaccine dosing strategies?

Certara's Vaccine Simulator uses biosimulation technology to integrate diverse inputs, allowing for optimized dosing strategies tailored to specific patient cohorts.

What is the current recommended dosing schedule for Pfizer-BioNTech and Moderna vaccines?

The current recommended dosing schedules are three weeks for Pfizer-BioNTech and four weeks for Moderna.

What future capabilities does Certara's Vaccine Simulator aim to provide?

The Vaccine Simulator aims to determine optimal timing for COVID-19 vaccine boosters and the best strategies for mixing and matching vaccines.

Who can benefit from Certara's biosimulation technology?

Global biopharmaceutical companies and regulatory agencies are primary users of Certara's biosimulation technology for vaccine and therapy development.